Key Details
The WHO Global Tuberculosis Report 2026 assesses the TB epidemic and progress towards global targets. The Health Ministry’s 12 November udpate provides additional India-specific programme figures.
India’s mortality rate: The Ministry, citing WHO estimates, reports a 38% decline since 2015, from approximately 28 to 18 deaths per lakh population by 2025. The published rates are rounded and do not, by themselves, reproduce the precise percentage.
Annual deaths: WHO says India reached at least a 35% reduction in the number of TB deaths between 2015 and 2025—the first End TB Strategy milestone, originally set for 2020.
Remaining burden: WHO estimates that India accounted for 23% of global TB deaths in 2025.
Treatment: The Ministry reports 94% treatment success among patients with drug-susceptible TB.
Campaign activity: From December 2024 to 8 November 2026, the Ministry says more than 25 crore people were brought within the ambit of screening activities. It reports over 11 crore chest X-rays, 3 crore rapid molecular tests and 48.64 lakh TB cases identified, including 14.97 lakh people described as asymptomatic.
The mortality rate measures deaths relative to population; the annual number counts deaths. The two reductions should not be treated as interchangeable.
Fewer Deaths, Alongside a Large Remaining Burden
WHO’s updated assessment places India among the high-TB-burden countries that achieved the first milestone for reducing the annual number of TB deaths. The Health Ministry’s more specific 38% figure refers to India’s mortality rate, based on estimates it attributes to WHO. WHO used newly available cause-of-death data from India’s Sample Registration System, supplemented by programme data, to update recent mortality estimates.
The improvement matters for a country that still accounted for nearly one in four TB deaths worldwide in 2025. It also needs to be viewed against the longer-term goal: the WHO End TB Strategy calls for a 90% reduction in annual TB deaths by 2030, compared with 2015.
Outreach Is Finding People Who May Not Seek Testing
Under the National TB Elimination Programme (NTEP), the intensified TB Mukt Bharat Abhiyaan began in high-priority districts in December 2024 and later expanded nationwide. A further phase launched in March 2026 focused on high-risk villages, urban wards and congregate settings.
The Ministry reports that 14.97 lakh of the cases identified through campaign activity were asymptomatic. This gives proactive screening a clear purpose: people without noticeable symptoms may have little reason to seek a test. Chest X-rays can identify people needing further assessment, while rapid molecular tests support diagnosis and prompt treatment. The campaign totals describe reported programme activity and case-finding, rather than WHO estimates of everyone who developed TB during the period.
Care continues after diagnosis. The Ministry reports 94% success in drug-susceptible TB treatment and describes nutritional assistance through Ni-kshay Poshan Yojana, community support through Ni-kshay Mitra, and patient tracking through the Ni-kshay platform. Together, these measures address barriers that can prevent patients from starting or completing treatment.
Surveillance Will Clarify Whether New Infections Are Falling
The WHO report has updated India’s mortality estimates, but says its 2010–2025 estimates of TB incidence — the number of people developing the disease each year — remain under review. India completed the first round of district-level sentinel surveillance in 2025, covering clusters in 50 districts. The Central TB Division, ICMR and WHO plan to analyse those findings before updating the incidence trend and India’s country profile.
This distinction matters when reading case counts. Finding more cases through intensified screening can increase reported diagnoses even if transmission is changing. Updated incidence estimates will provide a stronger basis for judging whether earlier detection and treatment are also producing a sustained decline in new TB disease.
Policy Relevance
India’s mortality progress shows the value of finding and treating TB, while the scale of remaining deaths keeps attention on continuity of care. For national and state programmes, the most useful measures now extend beyond the number of people reached by a campaign:
From screening to treatment: How many people with a positive screening result receive confirmatory testing, start treatment promptly and complete it?
Support for vulnerable patients: Are nutritional and community-support measures reaching people for whom illness, lost income or treatment costs make continued care difficult?
Evidence of reduced transmission: Do the new surveillance findings show that fewer people are developing TB, particularly in high-burden areas?
Follow the Full Report Here: WHO Global Tuberculosis Report 2026
Follow the Full Press Release Here: India Makes Major Strides Towards TB Elimination